Kurt Gustafson
Fortune : 783 188 $ au 31/05/2026
Fortune : 783 188 $ au 31/05/2026
Kurt A. Gustafson is currently Independent Director at Xencor, Inc. since 2014.
He is Chief Financial Officer & Executive VP-Finance at OmniAb Operations, Inc. and OmniAb, Inc., both since 2022.
Formerly, Mr. Gustafson was Independent Non-Executive Director at Niagen Bioscience, Inc. from 2016 to 2022.
He was Chief Financial Officer & Executive Vice President at Spectrum Pharmaceuticals, Inc. from 2013 to 2022.
He served as Chief Financial Officer & Vice President at Halozyme Therapeutics, Inc. from 2012 to 2013.
He was Chief Financial Officer & VP-Manufacturing Finance at Amgen, Inc. in 2009.
He held the position of Chief Financial Officer & Vice President-Finance at Amgen Europe BV from 2004 to 2006.
He worked at Amgen International AG as Chief Financial Officer, Treasurer & VP.
He was Staff Auditor at Horwath Velez & Co. PSC.
Education includes an MBA from the University of California, Los Angeles and an undergraduate degree from North Park University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OMNIAB, INC. 0,18% | 23/04/2026 | 261 483 ( 0,18% ) | 706 004 $ | 31/05/2026 |
XENCOR, INC. 0,01% | 28/02/2026 | 6 497 ( 0,01% ) | 77 184 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| XENCOR, INC. | Directeur/Membre du Conseil | 25/07/2014 |
| OMNIAB, INC. | Directeur Financier/CFO | 01/03/2022 |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology Develops drug discovery platform | Directeur Financier/CFO | 01/03/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| NIAGEN BIOSCIENCE, INC. | Directeur/Membre du Conseil | 16/06/2022 |
| SPECTRUM PHARMACEUTICALS, INC. | Directeur Financier/CFO | 18/03/2022 |
| HALOZYME THERAPEUTICS, INC. | Directeur Financier/CFO | 20/05/2013 |
| AMGEN INC. | Directeur Financier/CFO | 01/01/2009 |
Amgen Europe BV
Amgen Europe BV Medical DistributorsDistribution Services Wholesales pharmaceutical products | Directeur Financier/CFO | 01/01/2006 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 12 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel and targeted oncology & hematology drug products | Health Technology |
Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Xencor, Inc.
Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
North Park University
North Park University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Horwath Velez & Co. PSC
Horwath Velez & Co. PSC Miscellaneous Commercial ServicesCommercial Services Horwath Velez & Co. PSC is a private company based in Washington, DC. | Commercial Services |
Amgen Europe BV
Amgen Europe BV Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Chromadex Corp.
Chromadex Corp. Pharmaceuticals: OtherHealth Technology Acquires, develops and commercializes proprietary-based ingredient technologies | Health Technology |
Amgen International AG | |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology Develops drug discovery platform | Health Technology |
OmniAb, Inc.
OmniAb, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national